Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT
SHARE PURCHASE PURSUANT TO THE 2021 H SHARE AWARD AND TRUST SCHEME

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company hereby announces that, for the purpose of satisfying awards granted or to be granted under the Company's 2021 H Share Award and Trust Scheme approved and adopted by the shareholders of the Company (the "**Shareholders**") at the extraordinary general meeting of the Company held on September 23, 2021 and amended at the 2025 annual general meeting of the Company held on May 13, 2026 (the "**Scheme**"), the professional trustee appointed by the Company (the "**Trustee**") pursuant to the Scheme will purchase, through on-market transactions from time to time and in compliance with the Scheme and applicable laws and regulations, up to 15,000,000 H shares of the Company (the "**H Shares**") within 12 months from the date of this announcement for a total consideration of up to HKD360 million, with the specific timing, frequency, price, quantity and tranches to be determined by the Company and/or its authorised person(s) (the "**Share Purchase**").

The Company believes that the Share Purchase will support the effective operation of the Scheme and provide sufficient H Shares to satisfy awards granted or to be granted under the Scheme. The Company further considers that the Share Purchase reflects the Company's confidence in its business outlook and prospects and would, ultimately, benefit the Company and create value for the Shareholders. The Board believes that the Company has sufficient financial resources to implement the Share Purchase while maintaining a sound financial position.

The Share Purchase will be conducted in compliance with the terms of the Scheme, the articles of association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and other applicable laws and regulations.

Shareholders and potential investors should note that the Share Purchase is subject to market conditions and is at the absolute discretion of the Company and/or its authorised person(s), and there is no guarantee as to the timing, quantity or price of any Share Purchase. Therefore, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, November 24, 2026

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.